New Zealand markets close in 27 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.2900-0.4300 (-15.81%)
At close: 04:00PM EDT
2.3100 +0.02 (+0.87%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 433.86M
Enterprise value 476.24M
Trailing P/E N/A
Forward P/E 9.96
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.30
Price/book (mrq)74.89
Enterprise value/revenue 2.07
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.99
52-week change 372.18%
S&P500 52-week change 325.87%
52-week high 33.4000
52-week low 30.7000
50-day moving average 32.2810
200-day moving average 31.9407

Share statistics

Avg vol (3-month) 38.53M
Avg vol (10-day) 39.75M
Shares outstanding 5189.46M
Implied shares outstanding 6189.46M
Float 8164.35M
% held by insiders 10.52%
% held by institutions 168.91%
Shares short (15 May 2024) 424.91M
Short ratio (15 May 2024) 43.32
Short % of float (15 May 2024) 413.18%
Short % of shares outstanding (15 May 2024) 413.15%
Shares short (prior month 15 Apr 2024) 418.6M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin -37.65%
Operating margin (ttm)52.47%

Management effectiveness

Return on assets (ttm)-6.94%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)229.74M
Revenue per share (ttm)1.83
Quarterly revenue growth (yoy)466.10%
Gross profit (ttm)N/A
EBITDA -34.56M
Net income avi to common (ttm)-86.51M
Diluted EPS (ttm)-0.9000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)226.61M
Total cash per share (mrq)1.2
Total debt (mrq)548.87M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.22
Book value per share (mrq)-1.57

Cash flow statement

Operating cash flow (ttm)-27.3M
Levered free cash flow (ttm)-45.36M